Novel indazole non-nucleoside reverse transcriptase inhibitors using molecular hybridization based on crystallographic overlays

Journal of Medicinal Chemistry

Volumn 52, Issue 4, 2009, Pages 1219-1223

  Jones, Lyn H ^a   Allan, Gill ^a   Barba, Oscar ^a   Burt, Catherine ^a   Corbau, Romuald ^a   Dupont, Thomas ^a   Knöchel, Thorsten ^b   Irving, Steve ^a   Middleton, Donald S ^a   Mowbray, Charles E ^a   Perros, Manos ^a   Ringrose, Heather ^c   Swain, Nigel A ^a   Webster, Robert ^a   Westby, Mike ^a   Phillips, Chris ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b MERCK KGAA   (Germany)

^c Knights Court   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 (3 METHYL 1H INDAZOL 4 YLOXY) ISOPHTHALONITRILE; 5 (5 CHLORO 3 METHYL 1H INDAZOL 4 YLOXY) ISOPHTHALONITRILE; 5 (5 FLUORO 3 METHYL 1H INDAZOL 4 YLOXY) ISOPHTHALONITRILE; CAPRAVIRINE; EFAVIRENZ; INDAZOLE DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CRYSTAL STRUCTURE; CRYSTALLOGRAPHY; DRUG DESIGN; DRUG STABILITY; DRUG STRUCTURE; IC 50; MOLECULAR HYBRIDIZATION;

ANTI-HIV AGENTS; BENZOXAZINES; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; DRUG RESISTANCE, VIRAL; DRUG STABILITY; HIV; HIV REVERSE TRANSCRIPTASE; HUMANS; IMIDAZOLES; INDAZOLES; MOLECULAR STRUCTURE; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; SULFUR COMPOUNDS;

EID: 64349086788     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm801322h     Document Type: Article

References (24)

1. UNAIDS/WHO UNAIDS/WHO 2007 AIDS Epidemic Update, 2007.
2. De Clercq, E. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs): Past, Present and Future. Chem. Biodiversity 2004, 1, 44-64.
3. Bacheler, L.; Jeffrey, S.; Hanna, G.; D'Aquila, R.; Wallace, L.; Logue, K.; Cordova, B.; Hertogs, K.; Larder, B.; Buckery, R.; Baker, D.; Gallagher, K.; Scarnati, H.; Tritch, R.; Rizzo, C. Genotypic Correlates of Phenotypic Resistance to Efavirenz in Virus Isolates from Patients Failing Non-Nucleoside Reverse Transcriptase Inhibitor Therapy. J. Virol. 2001, 75, 4999-5008.
4. Haubrich, R.; Gubernick, S.; Yasothan, U.; Kirkpatrick, P. Etravirine. Nat. Rev. Drug Discovery 2008, 7, 287.
5. Fujiwara, T.; Sato, A.; El-Farrash, M.; Miki, S.; Abe, K.; Isaka, Y.; Kodama, M.; Wu, Y.; Chen, L. B.; Harada, H.; Sugimoto, H.; Hatanaka, M.; Hinumi, Y. S-1153 Inhibits Replication of Known Drug-Resistant Strains of Human Immunodeficiency Virus Type 1. Anti-microb. Agents Chemother. 1998, 42, 1340-1345.
6. Viegas-Junior, C.; Danuello, A.; Bolzani, V.; Barreiro, E. J.; Fraga, C. A. M. Molecular Hybrization: A Useful Tool in the Design of New Drug Prototypes. Curr. Med. Chem. 2007, 14, 1829-1852.
7. Boehm, H.-J.; Boehringer, M.; Bur, D.; Gmuender, H.; Huber, W.; Klaus, W.; Kostrewa, D.; Kuehne, H.; Luebbers, T.; Meunier-Keller, N.; Mueller, F. Novel Inhibitors of DNA Gyrase: 3D Structure Based Biased Needle Screening, Hit Validation by Biophysical Methods, and 3D Guided Optimization. A Promising Alternative to Random Screening. J. Med. Chem. 2000, 43, 2664-2674.
8. Bobik, A.; Holder, G. M.; Ryan, A. Inhibitors of Hepatic Mixed Function Oxidase. 3. Inhibition of Hepatic Microsomal Aniline Hydroxylase and Aminopyrine Demethylase by 2,6-and 2,4-Dihy-droxyphenyl Alkyl Ketones and Related Compounds. J. Med. Chem. 1977, 20, 1194-1199.
9. Ren, J.; Nichols, C.; Bird, L. E.; Fujiwara, T.; Sugimoto, H.; Stuart, D. I.; Stammers, D. K. Binding of the Second Generation Non-Nucleoside Inhibitor S-1153 to HIV-1 Reverse Transcriptase Involves Extensive Main Chain Hydrogen Bonding. J. Biol. Chem. 2000, 275, 14316-14320.
10. Ren, J.; Milton, J.; Weaver, K. L.; Short, S. A.; Stuart, D. I.; Stammers, D. K. Structural Basis for the Resilience of Efavirenz (DMP-266) to Drug Resistance Mutations in HIV-1 Reverse Transcriptase. Structure 2000, 8, 1089-1094.
11. Pelemans, H.; Esnouf, R.; De Clercq, E.; Balzarini, J. Mutational Analysis of Trp-229 of Human Immunodeficiency Virus Type 1 Reverse Transcriptase (RT) Identifies This Amino Acid Residue as a Prime Target for the Rational Design of New Non-Nucleoside RT Inhibitors. Mol. Pharm. 2000, 57, 954-960.
12. Fattorusso, C.; Gemma, S.; Butini, S.; Huleatt, P.; Catalanotti, B.; Persico, M.; De Angelis, M.; Fiorini, I.; Nacci, V.; Ramunno, A.; Rodriquez, M.; Greco, G.; Novellino, E.; Bergamini, A.; Marini, S.; Coletta, M.; Maga, G.; Spadari, S.; Campiani, G. Specific Targeting Highly Conserved Residues in the HIV-1 Reverse Transcriptase Primer Grip Region. Design, Synthesis and Biological Evaluation of Novel, Potent and Broad Spectrum NNRTIs with Antiviral Activity. J. Med. Chem. 2005, 48, 7153-7165.
13. (a) Jones, L. H.; Allan, G.; Corbau, R.; Hay, D.; Middleton, D. S.; Mowbray, C. E.; Newman, S.; Perros, M.; Randall, A.; Vuong, H.; Webster, R.; Westby, M.; Williams, D. Optimization of 5-aryloxy-imidazole non-nucleoside reverse transcriptase inhibitors. ChemMed-Chem 2008, 3, 1756-1762.
14. (b) Jones, L. H.; Randall, A.; Barba, O.; Selby, M. Synthetic chemistry-led creation of a difluorinated biaryl ether non-nucleoside reverse transcriptase inhibitor. Org. Biomol. Chem. 2007, 5, 3431-3433.
15. (c) Jones, L. H.; Dupont, T.; Mowbray, C. E.; Newman, S. A Concise and Selective Synthesis of Novel 5-Aryloxyimidazole NNRTIs. Org. Lett. 2006, 8, 1725-1727.
16. (d) Jones, L. H.; Mowbray, C. E. A concise synthesis of trifluormethyl-substituted 4-aryloxy pyrazoles. Synlett 2006, 9, 1404-1406.
17. Rekker, R. The Hydrophobic Fragmental Constant; Elsevier: Amsterdam, 1977.
18. Bu, H.-Z.; Pool, W. F.; Wu, E. Y.; Raber, S. R.; Amantea, M. A.; Shetty, B. V. Metabolism and excretion of capravirine, a new non-nucleoside reverse transcriptase inhibitor, alone and in combination with ritonavir in healthy volunteers. Drug Metab. Dispos. 2004, 32, 689.
19. Evans, D. C.; Watt, A. P.; Nicoll-Griffith, D. A.; Baille, T. A. Drug-Protein Adducts: An Industry Perspective on Minimizing the Potential for Drug Bioactivation in Drug Discovery and Development. Chem. Res. Toxicol. 2004, 17, 3-16.
20. Kalgutkar, A. S.; Gardner, I.; Obach, R. S.; Shaffer, C. L.; Callegari, E.; Henne, K. R.; Mutlib, A. E.; Dalvie, D. K.; Lee, J. S.; Nakai, Y.; O'Donnell, J. P.; Boer, J.; Harriman, S. P. A comprehensive listing of bioactivation pathways of organic functional groups. Curr. Drug Metab. 2005, 6, 161-225.
21. Coordinates have been deposited with the PDB and have the assigned code 2JLE.
22. The crystallographic overlay of 6 with capravirine and efavirenz fits perfectly the predicted binding mode: see Supporting Information.
23. Tucker, T. J.; Saggar, S.; Sisko, J. T.; Tynebor, R. M.; Williams, T. M.; Felock, P. J.; Flynn, J. A.; Lai, M.-T.; Liang, Y.; McGaughey, G.; Liu, M.; Miller, M.; Moyer, G.; Munshi, V.; Perlow-Poehnelt, R.; Prasad, S.; Sanchez, R.; Torrent, M.; Vacca, J. P.; Wan, B.-L.; Yan, Y. The design and synthesis of diaryl ether second generation HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) with enhanced potency versus key clinical mutations Bioorg. Med. Chem. Lett. 2008, 18, 2959-2966. These authors observed a notable reduction in potency for their lead compound against the clinically rare mutation Y181L, presumably due to interactions between the compound and the Y188 residue. We cannot rule out a similar mutant vulnerability as we have not measured Y188 mutant potencies.
24. Ren, J.; Chamberlain, P. P.; Stamp, A.; Short, S. A.; Weaver, K. L.; Romines, K. R.; Hazen, R.; Freeman, A.; Ferris, R. G.; Andrews, C. W.; Boone, L.; Chan, J. H.; Stammers, D. K. Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors. J. Med. Chem. 2008, 51, 5000-5008.